Alessandro A E Testori1, Stephanie A Blankenstein2, Alexander C J van Akkooi2. 1. Dermatology, Fondazione IRCCS Policlinico San Matteo, v.le Golgi 19, 27100, Pavia, Italy. info@alessandrotestori.it. 2. Department of Surgical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, Netherlands.
Abstract
PURPOSE OF REVIEW: This review describes the evolving role of surgery in stage III and IV melanoma. RECENT FINDINGS: Surgery has been the first option to cure melanoma patients at initial diagnosis of metastatic spread: a complete surgical excision of the disease either in stage III or IV has been the gold standard for decades. A positive sentinel node biopsy (SNB) has been followed by a complete lymph node dissection (CLND) since the early stages of modern surgical oncology. However, since two randomized trials have indicated that a CLND does not improve survival in patients with a positive SNB, a CLND is no longer considered mandatory. A therapeutic lymph node dissection (TLND) is still offered to patients with macroscopic nodal disease and in highly selected cases, patients with distant melanoma metastases can be treated surgically as well. Also the availability of adjuvant, and in the future possibly neoadjuvant, systemic therapy have shifted the landscape to less extensive surgery in metastatic melanoma. With the development of new systemic options, surgery in metastatic melanoma has become more and more part of a multidisciplinary treatment: surgical indications are moving from previous standards to a new role.
PURPOSE OF REVIEW: This review describes the evolving role of surgery in stage III and IV melanoma. RECENT FINDINGS: Surgery has been the first option to cure melanomapatients at initial diagnosis of metastatic spread: a complete surgical excision of the disease either in stage III or IV has been the gold standard for decades. A positive sentinel node biopsy (SNB) has been followed by a complete lymph node dissection (CLND) since the early stages of modern surgical oncology. However, since two randomized trials have indicated that a CLND does not improve survival in patients with a positive SNB, a CLND is no longer considered mandatory. A therapeutic lymph node dissection (TLND) is still offered to patients with macroscopic nodal disease and in highly selected cases, patients with distant melanoma metastases can be treated surgically as well. Also the availability of adjuvant, and in the future possibly neoadjuvant, systemic therapy have shifted the landscape to less extensive surgery in metastatic melanoma. With the development of new systemic options, surgery in metastatic melanoma has become more and more part of a multidisciplinary treatment: surgical indications are moving from previous standards to a new role.
Authors: Georgina V Long; Robyn P M Saw; Serigne Lo; Omgo E Nieweg; Kerwin F Shannon; Maria Gonzalez; Alexander Guminski; Jenny H Lee; Hansol Lee; Peter M Ferguson; Robert V Rawson; James S Wilmott; John F Thompson; Richard F Kefford; Sydney Ch'ng; Jonathan R Stretch; Louise Emmett; Rony Kapoor; Helen Rizos; Andrew J Spillane; Richard A Scolyer; Alexander M Menzies Journal: Lancet Oncol Date: 2019-06-03 Impact factor: 41.316
Authors: Christian U Blank; Elisa A Rozeman; Lorenzo F Fanchi; Karolina Sikorska; Bart van de Wiel; Pia Kvistborg; Oscar Krijgsman; Marlous van den Braber; Daisy Philips; Annegien Broeks; Johannes V van Thienen; Henk A Mallo; Sandra Adriaansz; Sylvia Ter Meulen; Loes M Pronk; Lindsay G Grijpink-Ongering; Annemarie Bruining; Rachel M Gittelman; Sarah Warren; Harm van Tinteren; Daniel S Peeper; John B A G Haanen; Alexander C J van Akkooi; Ton N Schumacher Journal: Nat Med Date: 2018-10-08 Impact factor: 53.440
Authors: Donald L Morton; Alistair J Cochran; John F Thompson; Robert Elashoff; Richard Essner; Edwin C Glass; Nicola Mozzillo; Omgo E Nieweg; Daniel F Roses; Harald J Hoekstra; Constantine P Karakousis; Douglas S Reintgen; Brendon J Coventry; He-jing Wang Journal: Ann Surg Date: 2005-09 Impact factor: 12.969
Authors: Alessandro Testori; Mark B Faries; John F Thompson; E Pennacchioli; Jan P Deroose; Albertus N van Geel; Cornelis Verhoef; Francesco Verrecchia; Javier Soteldo Journal: J Surg Oncol Date: 2011-09 Impact factor: 3.454
Authors: A Testori; J Soteldo; B Powell; F Sales; L Borgognoni; P Rutkowski; F Lejeune; Pam van Leeuwen; A Eggermont Journal: Ecancermedicalscience Date: 2013-03-28